里程碑式Helios-B三期研究新数据在2025年欧洲心脏病学会大会上发布,证实维特西然对ATTR-CM患者的长期心血管获益

美股速递
Aug 31

里程碑式Helios-B三期研究的最新数据在2025年欧洲心脏病学会大会上正式发布,研究结果证实了维特西然在治疗转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)方面具有显著的长期心血管获益效果。

这项重要研究为维特西然在ATTR-CM治疗领域的临床应用提供了更加坚实的科学依据,展现了该药物在改善患者长期心血管健康方面的积极作用。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10